South San Francisco, CA, November 7, 2023 – TeraPore Technologies, a leading nanofiltration innovator, has appointed Mani Krishnan as President and Chief Operating Officer (COO), effective October 2023. This has expanded his role within the company from board member to streamlining company operations and driving the commercial deployment of the IsoBlock® VF product line. He remains an active board member.
IsoBlock® VF was engineered to address the challenges of virus filtration using proprietary Intelligent Membrane™ technology to provide broad compatibility and consistent performance in a gamma irradiated, easy-to-use, familiar format. The self-assembled isoporous membrane structure and surface chemistry were developed to minimize fouling, while providing high parvovirus retention, resulting in stable and predictable VF performance.
“TeraPore is at an inflection point as we prepare to launch our disruptive virus filtration products into the biopharmaceutical market. Mani has been an active advisor for over a year, providing valuable insight and access across the industry,” Rachel Dorin, Founder and CEO of TeraPore Technologies said. “We are delighted for Mani to join our team and bring his wealth of experience in the biopharmaceutical industry as we build out our commercial capabilities.”
“While on the board I have had the pleasure of spending considerable time with the talented TeraPore team. The positive team environment and proprietary self-assembled block copolymer technology are what convinced me to step out of retirement and take on this exciting challenge,” said new President and COO, Mani Krishnan. “As I settle into this role, my priority will be to provide the team with the tools that they need to bring this exciting technology to our biopharmaceutical customers. We will take a continuous learning approach to providing a novel solution for a challenging application in the highly regulated bioprocessing market, while also looking to expand the promise of this technology in other critical separation applications.”
Research, development, and manufacturing operations are situated in the South San Francisco, California headquarters. All critical components of IsoBlock® VF, including the polymers used to fabricate the isoporous membrane, are manufactured and assembled in house, offering unparalleled supply-chain security.
The IsoBlock® VF Syringe Evaluation Kit is poised to launch next month. To learn more, please visit www.terapore.com/products or email contact@terapore.com.